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Mutations of ALK are frequently observed in MYCN-amplified neuroblastomas and correlate with poor
clinical outcome, but how these oncogenes cooperate in neuroblastoma development remains unclear. In
this issue of Cancer Cell, Zhu et al. describe a mechanism by which ALK and MYCN synergistically induce
neuroblastoma in the zebrafish model system.Neuroblastoma (NB) is the most common
childhood malignant solid tumor of the
sympathetic nervous system (Maris,
2010). Numerous chromosomal abnor-
malities, including deletions of chromo-
some arms 1p, 11q, gain of 17q, and
amplification of MYCN on chromosome
2p, are associated with NB. The overall
prevalence of MYCN amplification is
about 20% and is a genetic marker of
poor prognosis that has been used for
treatment stratification of NB patients
since the late 1980s (Maris, 2010). During
the past 40 years, the outcome of children
with high-risk NB has shown marked
improvements. However, the 5 year
event-free survival is only 50% for these
patients, and there are significant toxic-
ities associated with current treatments.
Until recently, no recurrent mutations in
druggable targets had been identified.
The discovery of activating mutations in
the ALK oncogene in both hereditary
(80%) and sporadic (7%–8%) NB pro-
vides an opportunity for targeted therapy
(reviewed in Azarova et al., 2011).
The ALK oncogene was identified
initially as a gene that fused with NPM
through 2;5 chromosome translocation in
cases of anaplastic large-cell lymphoma
(Morris et al., 1994). Although the wild-
type (WT) ALK is preferentially expressed
in the central and peripheral nervous
systems, its physiologic role, ligands,
and signaling pathways remain largely
obscure (Azarova et al., 2011). In a series
of elegant studies, activating mutations in
ALK were identified in primary NB tumors,
and their oncogenic potential was dem-
onstrated. WT ALK was also thought to
possess oncogenic activity in NB cells
when its expression level surpasses a
threshold (Azarova et al., 2011).A question in the field has beenwhether
ALK mutations alone are sufficient to
cause neuroblastoma. The finding that
ALKmutations occur in equal frequencies
across all genomic NB subtypes and in
both low- and high-risk tumors seemed
to be inconsistent with ALK being the
sole ‘‘driver’’ oncogene in NB. One clue
came with the finding that a common
mutation ALK F1174L is observed at
a higher frequency in MYCN-amplified
tumors (Azarova et al., 2011). Moreover,
overexpression of WT or mutant ALK
stimulated MYCN transcription in neuro-
blastoma cell lines, and coexpressing
activated ALK and MYCN increased NIH
3T3 cell transformation in vitro (Scho¨nherr
et al., 2012). Amplification of ALK also
occurs in about 2%–3% of NB, but
almost exclusively in those with MYCN-
amplification (Azarova et al., 2011). Taken
together, these studies raised the possi-
bility of a positive cooperative effect
between the dysregulation of both ALK
and MYCN.
In this issue of Cancer Cell, Zhu et al.
(2012) explore these questions by gener-
ating a series of transgenic zebrafish
models to assess the tumorigenicity of
ALK, ALK F1174L, and MYCN alone or
together. Using the dopamine-b-hydrox-
ylase promoter to drive EGFP-MYCN
expression, Zhu et al. (2012) first investi-
gated whether MYCN transgenic zebra-
fish can develop NB as had been shown
in mice (Weiss et al., 1997). They showed
that MYCN-induced zebrafish NB at a low
frequency (17.3%), with these tumors
sharing histologic, immunocytochemical,
and ultrastructural features with human
NB. Zebrafish NB arise from neuroblasts
that migrate into the interrenal gland
(equivalent to the human adrenal gland)Cancer Cell 2late in development (21 days post
fertilization), and the sympathoadrenal
precursors coexpress neuronal-specific
Hu proteins and the catecholaminergic
enzymes TH and DbH.
Zebrafish expressing ALK or ALK
F1174L transgene alone did not develop
NB. To address whether ALK and MYCN
genetically interact, Zhu et al. (2012)
generated transgenic zebrafishes that ex-
pressed the human ALK, or ALK F1174L,
together with MYCN. Tumor onset was
accelerated in fish expressing both
MYCN and ALK F1174L compared to
those expressing MCYN alone, and the
penetrance in the MYCN/ALK F1174L
fish was 3-fold higher than MYCN fish.
Like the tumors in the MYCN fishes,
tumors in MYCN/ALK F1174L fish arise
in the interrenal gland and resemble
human NB. This suggests that ALK muta-
tions may be ‘‘initiating’’ events and need
a ‘‘second hit’’, such as dysregulated
MYCN, to fully transform cells. This pro-
vides a context which might explain the
findings of ALK mutations in the tumors
of low risk, good prognosis NB patients.
So how does ALK accelerate tumor
onset and increase penetrance in MYCN
transgenic fish? Zhu et al. (2012) found
that the number of Hu+ neuroblasts was
significantly increased in MYCN trans-
genic fish compared with controls at
3–5 weeks post fertilization (wpf) (Fig-
ure 1). These MYCN-overexpressing neu-
roblasts fail to differentiate, resulting in
reduced numbers of chromaffin cells.
Moreover, at 5–7 wpf, the number of
Hu+ neuroblasts in the interrenal gland
decreased significantly due to apoptotic
cell death. These findings indicate that
overexpression of MYCN causes ex-
pansion of sympathoadrenal neuroblasts1, March 20, 2012 ª2012 Elsevier Inc. 325
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Figure 1. MYCN and ALK F1174L Synergistically Impact Neuroblastoma Tumorigenesis
In zebrafish, theMYCN overexpression causes expansion of the sympathoadrenal neuroblasts from 3 to 5
wpf, and the MYCN overexpressing neuroblasts fail to differentiate into chromaffin cells. Only a small
group of zebrafish (17%) with MYCN overexpression developed neuroblastoma; others won’t because
MYCN overexpression also triggers an apoptotic response at 5.5 wpf. The activated ALK F1174L provides
a cell survival signal that blocks the apoptotic response of MYCN-overexpressing neuroblasts at this junc-
ture in development, so the tumor penetrance in the MYCN/ALK F1174L coexpressing transgenic fish is
3-fold higher (56%).
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also induces a developmentally-timed
apoptotic response (Figure 1). However,
in the presence of activated ALK, these
cells survive but fail to differentiate result-
ing in the continued accumulation of
Hu+ neuroblasts and the development of
highly penetrant, fully transformed NB
(Figure 1). For the MYCN-only transgenic
fish that develop tumors, it is possible
that additional genetic alterations coop-
erate with MYCN to contribute to NB
formation. Zhu et al. (2012) ruled out
mutations in the tyrosine kinase domain
of the zebrafish alk gene and loss of
capsase-8 expression that is known to
occur in MYCN-amplified human NB.
Thus, other genetic mutations or epige-
netic events that activate prosurvival
pathways may occur with MYCN overex-
pression in these tumors. In fact, recent
studies showed that the Myc family
(including MYCN) directly upregulates
the transcription of all core components
of the Polycomb Repressive Complex 2
(PRC2) to maintain embryonic stem cell326 Cancer Cell 21, March 20, 2012 ª2012 Epluripotency (Neri et al., 2012). Dysregula-
tion of EZH2 (a subunit of PRC2) has been
shown to silence differentiation-associ-
ated genes with tumor suppressor activity
in undifferentiated humanNB (Wang et al.,
2012). In this zebrafish model system, WT
or activated ALK expression alone is not
sufficient for the development of NB
but requires overexpression of MYCN. It
remains to be clarified if increased ex-
pression of ALK via the use of a stronger
promoter or protein stabilization will result
in tumorigenesis on its own.
The results from Zhu et al. (2012)
demonstrate that ALK and MYCN collab-
oratively contribute to NB development,
with ALK F1174L attenuating MYCN-
induced apoptosis perhaps by activating
pro-survival pathways. A clinical PhaseI/
II trial targeting ALK is underway in chil-
dren with solid tumors, including those
with NB using Crizotinib, the FDA-
approved ALK/MET inhibitor. Given the
clinical experience with targeted agents
and the development of drug resistance,
it is unlikely that targeting ALK alone willlsevier Inc.lead to durable responses. Multi-modality
therapeutic approaches will be needed.
The general view has been that tran-
scription factors such as MYCN are less
amenable to targeted therapeutic ap-
proaches. However, the recent identifica-
tion of inhibitors of BET (bromodomain
and extraterminal subfamily of human
bromodomain proteins), which decrease
MYCN mRNA levels in MYCN-amplified
NB cell lines (Mertz et al., 2011) and
strategies to destabilize MYCN protein
(Hogarty and Maris, 2012), indicate it
may be feasible to target MYCN. The
zebrafish MYCN-ALK F1174L NB tumor
model serves not only to understand
developmental alterations leading to
tumor formation but it can also serve as
a platform for evaluating unbiased drug
screens as well as the next generation of
targeted approaches.REFERENCES
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